


This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

Claims 1-10 (Cancelled)

11. (Currently Amended): A method for treating leukemia in a host comprising:
administering to the host having leukemia a therapeutically effective amount of
cytarabine; ~~and~~
at least one compound of general formula I



wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, and



wherein each Rc is independently selected from the group comprising H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl and hydroxy protecting groups, and wherein said compound is substantially in the form of the (-) enantiomer; and
a further agent selected from PSC 833, monoclonal antibodies, cytokines, Rituxan,

CMA-76, Interferon-alpha recombinant, Interleukin-2, Interleukin-3, Erythropoetin, Epoetin, G-CSF, GM-CSF, Filgrastim, Sargramostim and Thrombopoietin.

12. (Previously Presented): A method according to claim 11, wherein the leukemia is chronic myelogenous leukemia.

13. (Previously Presented): A method according to claim 11, wherein the leukemia is acute myelogenous leukemia.

14. (Cancelled):

15. (Currently Amended): A method according to claim 14, wherein said further agent ~~the multidrug resistance agent~~ is PSC 833.

16. (Currently Amended): A method according to claim 14, wherein said further agent ~~is the biological response modifiers~~ are selected from the group consisting of monoclonal antibodies and cytokines.

17. (Currently Amended): A method according to claim 14, wherein said the cytokines are selected from ~~the group consisting of~~ interferons, interleukins and colony-stimulating factors.

18. (Currently Amended): A method according to claim 14, wherein said further agent ~~is the biological response modifiers~~ are selected from ~~the group consisting of~~ Rituxan, CMA-676, Interferon-alpha recombinant, Interleukin-2, Interleukin-3, Erythropoetin, Epoetin, G-CSF, GM-CSF, Filgrastim, Sargramostim and Thrombopoietin.

19. (Previously Presented): A method according to claim 11, wherein the

compound of formula I and cytarabine are administered sequentially.

20. (Previously Presented): A method according to claim 11, wherein the compound of formula I and cytarabine are administered simultaneously.

21. (Previously Presented): A method according to claim 11, wherein said compound is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.

22. (Withdrawn): A method according to claim 21, wherein said compound is (-)- β -Dioxolane-5-fluoro-Cytidine (5-FddC).

23. (Previously Presented): A method according to claim 11, wherein said compound is at least 97% free of the corresponding (+) enantiomer.

24. (Previously Presented): A method according to claim 11, wherein said compound is at least 99% free of the corresponding (+) enantiomer.

25. (Previously Presented): A method according to claim 21, wherein said compound is at least 97% free of the corresponding (+) enantiomer.

26. (Previously Presented): A method according to claim 21, wherein said compound is at least 99% free of the corresponding (+) enantiomer.

27. (Cancelled):

28. (Cancelled):

29. (Cancelled):

30. (Cancelled):

31. (Cancelled):
32. (Cancelled):
33. (Cancelled):
34. (Previously Presented): A method according to claim 12, wherein said compound is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.
35. (Previously Presented): A method according to claim 13, wherein said compound is (-)- β -L-Dioxolane-Cytidine (β -L-oddC) or a pharmaceutically acceptable salt thereof.
36. (Withdrawn): A method according to claim 12, wherein said compound is (-)- β -Dioxolane-5-fluoro-Cytidine (5-FddC) or a pharmaceutically acceptable salt thereof.
37. (Previously Presented): A method according to claim 35, wherein said compound is (-)- β -L-Dioxolane-Cytidine (β -L-oddC).
38. (Cancelled):
39. (Cancelled):
40. (Cancelled):
41. (Cancelled):

42. (Cancelled):

43. (Cancelled):

44. (Cancelled):

45. (Cancelled):

46. (Cancelled):

47. (Cancelled):

48. (Cancelled):

49. (Cancelled):

50. (Cancelled):